PharmaVoice Logo

Healthcare Leaders Hub

Erasca Reports Updated P-I (AURORAS-1) Data of ERAS-0015 for RAS-Mutant Solid Tumors

PharmaShots

Erasca Reports Updated P-I (AURORAS-1) Data of ERAS-0015 for RAS-Mutant Solid Tumors

Shots: Ref: GlobeNewswire  |   Image: Erasca  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Erasca Reports Updated P-I (AURORAS-1) Data of ERAS-0015 for RAS-Mutant Solid Tumors appeared first on PharmaShots.

Read Full Article
Savara Reports the US FDA Will Not Act on Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis by the PDUFA Date

PharmaShots

Savara Reports the US FDA Will Not Act on Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis by the PDUFA Date

Shots: Ref: Business Wire  |   Image: Savara  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Savara Reports the US FDA Will Not Act on Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis by the PDUFA Date appeared first on PharmaShots.

Read Full Article
Belite Bio Reports Three-Month Extension of the US FDA Review of Tinlarebant NDA for Stargardt Disease Type 1

PharmaShots

Belite Bio Reports Three-Month Extension of the US FDA Review of Tinlarebant NDA for Stargardt Disease Type 1

Shots: Ref: GlobeNewswire  |   Image: Belite Bio  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Belite Bio Reports Three-Month Extension of the US FDA Review of Tinlarebant NDA for Stargardt Disease Type 1 appeared first on PharmaShots.

Read Full Article
Merck’s Sacituzumab Tirumotecan (Sac-TMT) Meets Primary Endpoint of Overall Survival in P-III TroFuse-015 Trial for Gastroesophageal Adenocarcinoma

PharmaShots

Merck’s Sacituzumab Tirumotecan (Sac-TMT) Meets Primary Endpoint of Overall Survival in P-III TroFuse-015 Trial for Gastroesophageal Adenocarcinoma

Shots: Ref: Merck  |   Image: Merck  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Merck’s Sacituzumab Tirumotecan (Sac-TMT) Meets Primary Endpoint of Overall Survival in P-III TroFuse-015 Trial for Gastroesophageal Adenocarcinoma appeared first on PharmaShots.

Read Full Article
Building a Pharma Cleanroom Facility: Why IT Hardware Belongs in the Design Phase

PharmaShots

Building a Pharma Cleanroom Facility: Why IT Hardware Belongs in the Design Phase

When a pharmaceutical or biotech cleanroom is designed, the attention naturally goes to the big systems: the HVAC and its pressure cascade, the room layout and personnel flows, the wall and ceiling panel system, the floor finish and the process equipment. Computers, screens and scanners tend to appear late, often as an item on the… The post Building a Pharma Cleanroom Facility: Why IT Hardware Belongs in the Design Phase appeared first on PharmaShots.

Read Full Article

Sponsored content

Featured promotional

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer

News

Latest stories

Pharma Tech

Nov 20, 2026, 4:46 PM

Preventative healthcare powers new wave of UK regulatory reform 

Speakers at the 2026 DIA-MHRA Global Summit talked of a healthcare system overhaul with preventative medicine at the core.

PharmaShots

Nov 20, 2026, 4:17 PM

Erasca Reports Updated P-I (AURORAS-1) Data of ERAS-0015 for RAS-Mutant Solid Tumors

Shots: Ref: GlobeNewswire  |   Image: Erasca  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Erasca Reports Updated P-I (AURORAS-1) Data of ERAS-0015 for RAS-Mutant Solid Tumors appeared first on PharmaShots.

PharmaShots

Nov 20, 2026, 4:10 PM

Savara Reports the US FDA Will Not Act on Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis by the PDUFA Date

Shots: Ref: Business Wire  |   Image: Savara  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Savara Reports the US FDA Will Not Act on Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis by the PDUFA Date appeared first on PharmaShots.

PharmaShots

Nov 20, 2026, 4:05 PM

Belite Bio Reports Three-Month Extension of the US FDA Review of Tinlarebant NDA for Stargardt Disease Type 1

Shots: Ref: GlobeNewswire  |   Image: Belite Bio  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Belite Bio Reports Three-Month Extension of the US FDA Review of Tinlarebant NDA for Stargardt Disease Type 1 appeared first on PharmaShots.

PharmaShots

Nov 20, 2026, 4:04 PM

Merck’s Sacituzumab Tirumotecan (Sac-TMT) Meets Primary Endpoint of Overall Survival in P-III TroFuse-015 Trial for Gastroesophageal Adenocarcinoma

Shots: Ref: Merck  |   Image: Merck  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Merck’s Sacituzumab Tirumotecan (Sac-TMT) Meets Primary Endpoint of Overall Survival in P-III TroFuse-015 Trial for Gastroesophageal Adenocarcinoma appeared first on PharmaShots.

Pharma Tech

Nov 20, 2026, 2:59 PM

MSD and Isomorphic join forces to develop oncology drugs 

MSD inks this deal as it looks to offset the looming impact of Keytruda’s patent expiry and secure its long-term growth prospects.

News

Latest industry coverage

Google News

Nov 22, 2026, 6:13 PM

TEVA Investors Have Opportunity to Join Teva Pharmaceutical Industries Limited Fraud Investigation with SBS Law - Carroll County Mirror-Democrat

TEVA Investors Have Opportunity to Join Teva Pharmaceutical Industries Limited Fraud Investigation with SBS Law  Carroll County Mirror-Democrat

Google News

Nov 22, 2026, 5:14 PM

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey - MarketScale

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey  MarketScale

Google News

Nov 22, 2026, 3:46 PM

Powder Dispensers Market To 2035: Precision Dosing Demand Supports Forward Growth - News and Statistics - IndexBox

Powder Dispensers Market To 2035: Precision Dosing Demand Supports Forward Growth - News and Statistics  IndexBox

Google News

Nov 22, 2026, 3:06 PM

Ethiopia Targets Skilled Workforce to Drive Pharmaceutical Industry Expansion - ENA English

Ethiopia Targets Skilled Workforce to Drive Pharmaceutical Industry Expansion  ENA English

Google News

Nov 22, 2026, 1:45 PM

Govt Proposes Relaxing Schedule M Requirements for Medicinal Gases, Capsules and Disinfectants - Medical Dialogues

Govt Proposes Relaxing Schedule M Requirements for Medicinal Gases, Capsules and Disinfectants  Medical Dialogues

Google News

Nov 22, 2026, 1:30 PM

Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20% - Fortune

Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%  Fortune

Google News

Nov 22, 2026, 12:34 PM

Manufacturers see red over NPPA's frequent use of emergency pricing powers - Business Standard

Manufacturers see red over NPPA's frequent use of emergency pricing powers  Business Standard

Google News

Nov 22, 2026, 12:04 PM

Peptide drug runs can stall on late raw materials, Frost & Sullivan and Medtide find - MarketScale

Peptide drug runs can stall on late raw materials, Frost & Sullivan and Medtide find  MarketScale

Google News

Nov 22, 2026, 12:00 PM

‘I don’t blame any woman for being sucked in’: how the wellness industry is cynically exploiting menopause - The Guardian

‘I don’t blame any woman for being sucked in’: how the wellness industry is cynically exploiting menopause  The Guardian

Sponsored placement

Featured promotions

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer